

Daniel E Gomez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11271968/publications.pdf>

Version: 2024-02-01

56
papers

2,090
citations

230014

27
h-index

286692

43
g-index

56
all docs

56
docs citations

56
times ranked

2635
citing authors

#	ARTICLE	IF	CITATIONS
1	New inhibitor targeting Acyl-CoA synthetase 4 reduces breast and prostate tumor growth, therapeutic resistance and steroidogenesis. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 2893-2910.	2.4	31
2	Computational and in vitro Pharmacodynamics Characterization of 1A-116 Rac1 Inhibitor: Relevance of Trp56 in Its Biological Activity. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 240.	1.8	7
3	Telomeropathies: Etiology, diagnosis, treatment and follow-up. Ethical and legal considerations. <i>Clinical Genetics</i> , 2019, 96, 3-16.	1.0	17
4	Preclinical Efficacy of [V4 Q5]dDAVP, a Second Generation Vasopressin Analog, on Metastatic Spread and Tumor-Associated Angiogenesis in Colorectal Cancer. <i>Cancer Research and Treatment</i> , 2019, 51, 438-450.	1.3	15
5	AZT exerts its antitumoral effect by telomeric and non-telomeric effects in a mammary adenocarcinoma model. <i>Oncology Reports</i> , 2016, 36, 2731-2736.	1.2	13
6	Addition of vasopressin synthetic analogue [V4Q5]dDAVP to standard chemotherapy enhances tumour growth inhibition and impairs metastatic spread in aggressive breast tumour models. <i>Clinical and Experimental Metastasis</i> , 2016, 33, 589-600.	1.7	12
7	A phase II dose-escalation trial of perioperative desmopressin (1-desamino-8-d-arginine vasopressin) in breast cancer patients. <i>SpringerPlus</i> , 2015, 4, 428.	1.2	34
8	The novel desmopressin analogue [V4Q5]dDAVP inhibits angiogenesis, tumour growth and metastases in vasopressin type 2 receptor-expressing breast cancer models. <i>International Journal of Oncology</i> , 2015, 46, 2335-2345.	1.4	28
9	Preclinical Development of Novel Rac1-GEF Signaling Inhibitors using a Rational Design Approach in Highly Aggressive Breast Cancer Cell Lines. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2014, 14, 840-851.	0.9	67
10	Proapoptotic and antiinvasive activity of Rac1 small molecule inhibitors on malignant glioma cells. <i>OncoTargets and Therapy</i> , 2014, 7, 2021.	1.0	26
11	Protein universe containing a PUA RNA-binding domain. <i>FEBS Journal</i> , 2014, 281, 74-87.	2.2	18
12	Mechanisms of Cellular Uptake, Intracellular Transportation, and Degradation of CIGB-300, a Tat-Conjugated Peptide, in Tumor Cell Lines. <i>Molecular Pharmaceutics</i> , 2014, 11, 1798-1807.	2.3	18
13	Structure-activity relationship of 1-desamino-8-D-arginine vasopressin as an antiproliferative agent on human vasopressin V2 receptor-expressing cancer cells. <i>Molecular Medicine Reports</i> , 2014, 9, 2568-2572.	1.1	13
14	Insight into the effect of the vasopressin analog desmopressin on lung colonization by mammary carcinoma cells in BALB/c mice. <i>Anticancer Research</i> , 2014, 34, 4761-5.	0.5	13
15	Reduction of tumor angiogenesis induced by desmopressin in a breast cancer model. <i>Breast Cancer Research and Treatment</i> , 2013, 142, 9-18.	1.1	34
16	Anti-idiotypic antibodies in cancer treatment. <i>Frontiers in Oncology</i> , 2013, 3, 37.	1.3	2
17	Telomerase regulation: A key to inhibition?. <i>International Journal of Oncology</i> , 2013, 43, 1351-1356.	1.4	18
18	Preclinical evaluation of racotumomab, an anti-idiotypic monoclonal antibody to N-glycolyl-containing gangliosides, with or without chemotherapy in a mouse model of non-small cell lung cancer. <i>Frontiers in Oncology</i> , 2012, 2, 160.	1.3	16

#	ARTICLE	IF	CITATIONS
19	AZT as a telomerase inhibitor. <i>Frontiers in Oncology</i> , 2012, 2, 113.	1.3	45
20	Racotumomab: an anti-idiotypic vaccine related to N-glycolyl-containing gangliosides – preclinical and clinical data. <i>Frontiers in Oncology</i> , 2012, 2, 150.	1.3	30
21	Cancer Antigen Prioritization: A Road Map to Work in Defining Vaccines Against Specific Targets. A Point of View. <i>Frontiers in Oncology</i> , 2012, 2, 66.	1.3	9
22	Telomere structure and telomerase in health and disease. <i>International Journal of Oncology</i> , 2012, 41, 1561-1569.	1.4	126
23	Sensitivity of tumor cells towards CIGB-300 anticancer peptide relies on its nucleolar localization. <i>Journal of Peptide Science</i> , 2012, 18, 215-223.	0.8	28
24	The Functional Interaction between Acyl-CoA Synthetase 4, 5-Lipoxygenase and Cyclooxygenase-2 Controls Tumor Growth: A Novel Therapeutic Target. <i>PLoS ONE</i> , 2012, 7, e40794.	1.1	51
25	Antitumor protection by NGcGM3/VSSP vaccine against transfected B16 mouse melanoma cells overexpressing N-glycolylated gangliosides. <i>In Vivo</i> , 2012, 26, 609-17.	0.6	14
26	Effect of atorvastatin in a case of feline multicentric lymphoma – Case report. <i>Acta Veterinaria Hungarica</i> , 2011, 59, 69-76.	0.2	0
27	Effect of Adjuvant Perioperative Desmopressin in Locally Advanced Canine Mammary Carcinoma and its Relation to Histologic Grade. <i>Journal of the American Animal Hospital Association</i> , 2011, 47, 21-27.	0.5	32
28	CIGB-300, a proapoptotic peptide, inhibits angiogenesis in vitro and in vivo. <i>Experimental Cell Research</i> , 2011, 317, 1677-1688.	1.2	20
29	Antiproliferative effect of 1-deamino-8-D-arginine vasopressin analogs on human breast cancer cells. <i>Future Medicinal Chemistry</i> , 2011, 3, 1987-1993.	1.1	28
30	CIGB-300, a synthetic peptide-based drug that targets the CK2 phosphoacceptor domain. Translational and clinical research. <i>Molecular and Cellular Biochemistry</i> , 2011, 356, 45-50.	1.4	41
31	NGcGM3 Ganglioside: A Privileged Target for Cancer Vaccines. <i>Clinical and Developmental Immunology</i> , 2010, 2010, 1-8.	3.3	67
32	Effects of the synthetic vasopressin analog desmopressin in a mouse model of colon cancer. <i>Anticancer Research</i> , 2010, 30, 5049-54.	0.5	16
33	Exogenous incorporation of neugc-rich mucin augments n-glycolyl sialic acid content and promotes malignant phenotype in mouse tumor cell lines. <i>Journal of Experimental and Clinical Cancer Research</i> , 2009, 28, 146.	3.5	18
34	Systemic administration of a peptide that impairs the protein kinase (CK2) phosphorylation reduces solid tumor growth in mice. <i>International Journal of Cancer</i> , 2008, 122, 57-62.	2.3	64
35	Perioperative desmopressin prolongs survival in surgically treated bitches with mammary gland tumours: A pilot study. <i>Veterinary Journal</i> , 2008, 178, 103-108.	0.6	32
36	Enhanced cytostatic activity of statins in mouse mammary carcinoma cells overexpressing β 2-chimaerin. <i>Molecular Medicine Reports</i> , 2008, 2, 97-102.	1.1	7

#	ARTICLE	IF	CITATIONS
37	Antitumor effects of desmopressin in combination with chemotherapeutic agents in a mouse model of breast cancer. <i>Anticancer Research</i> , 2008, 28, 2607-11.	0.5	16
38	Complete Antitumor Protection by Perioperative Immunization with GM3/VSSP Vaccine in a Preclinical Mouse Melanoma Model. <i>Clinical Cancer Research</i> , 2006, 12, 7092-7098.	3.2	21
39	Active Specific Immunotherapy of Melanoma with a GM3 Ganglioside-Based Vaccine. <i>Journal of Immunotherapy</i> , 2004, 27, 442-451.	1.2	39
40	Ganglioside-based vaccines and anti-idiotypic antibodies for active immunotherapy against cancer. <i>Expert Review of Vaccines</i> , 2003, 2, 817-823.	2.0	30
41	Inhibition of aggressiveness of metastatic mouse mammary carcinoma cells by the beta2-chimaerin GAP domain. <i>Cancer Research</i> , 2003, 63, 2284-91.	0.4	39
42	Desmopressin inhibits lung and lymph node metastasis in a mouse mammary carcinoma model of surgical manipulation. <i>Journal of Surgical Oncology</i> , 2002, 81, 38-44.	0.8	36
43	Lovastatin alters cytoskeleton organization and inhibits experimental metastasis of mammary carcinoma cells. <i>Clinical and Experimental Metastasis</i> , 2002, 19, 551-560.	1.7	58
44	Cancer vaccines: an update with special focus on ganglioside antigens. <i>Oncology Reports</i> , 2002, 9, 267-76.	1.2	60
45	Chronic In Vitro Exposure to 3-azido-2,3-dideoxythymidine Induces Senescence and Apoptosis and Reduces Tumorigenicity of Metastatic Mouse Mammary Tumor Cells. <i>Breast Cancer Research and Treatment</i> , 2001, 65, 93-99.	1.1	36
46	In Vitro Activity of a Solanum tuberosum Extract against Mammary Carcinoma Cells. <i>Planta Medica</i> , 2001, 67, 164-166.	0.7	5
47	Tissue inhibitor of metalloproteinases-1 promotes liver fibrosis development in a transgenic mouse model. <i>Hepatology</i> , 2000, 32, 1248-1254.	3.6	233
48	Antimetastatic effect of desmopressin in a mouse mammary tumor model. <i>Breast Cancer Research and Treatment</i> , 1999, 57, 271-275.	1.1	32
49	Modulation of urokinase-type plasminogen activator and metalloproteinase activities in cultured mouse mammary-carcinoma cells: Enhancement by paclitaxel and inhibition by nocodazole. , 1999, 83, 242-246.		11
50	Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis. <i>Breast Cancer Research and Treatment</i> , 1998, 50, 83-93.	1.1	135
51	Mammary carcinoma cells over-expressing tissue inhibitor of metalloproteinases-1 show vascular endothelial growth factor expression. , 1998, 75, 81-87.		111
52	Irreversible Telomere Shortening by 3-azido-2,3-dideoxythymidine (AZT) Treatment. <i>Biochemical and Biophysical Research Communications</i> , 1998, 246, 107-110.	1.0	80
53	Enhanced RNA expression of tissue inhibitor of metalloproteinases-1 (TIMP-1) in human breast cancer. , 1996, 69, 131-134.		52
54	Alterations in endothelial cell proteinase and inhibitor polarized secretion following treatment with interleukin-1, phorbol ester, and human melanoma cell conditioned medium. , 1996, 60, 148-160.		8

#	ARTICLE	IF	CITATIONS
55	Tumor invasion, proteolysis, and angiogenesis. <i>Journal of Neuro-Oncology</i> , 1994, 18, 89-103.	1.4	63
56	Immunomagnetic separation as a final purification step of liver endothelial cells. <i>In Vitro Cellular & Developmental Biology</i> , 1993, 29, 451-455.	1.0	15